In this issue
Predicting response of molecular targeted therapies: a still possible challenge?
Developing innovative models for North–South cooperation in clinical research—experience from the INDOX Cancer Research Network
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables
A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207
Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes
A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management
Optimisation of circulating biomarkers of cell death for routine clinical use
Cigarette smoking and site-specific cancer mortality: testing uncertain associations using extended follow-up of the original Whitehall study
Alcohol consumption and renal cell cancer risk in two Italian case–control studies
Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim
ErbB/HER receptor family in breast cancer—the more we search the more we learn
Factors influencing the decision to take or reject opioids for cancer pain: are we on target?
Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy
MR imaging features of invasive breast cancer correlated with hormonal receptors: does progesterone receptor matter?
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine
corrigendum
corrigendum